Eur Urol Suppl 2008;7(3):218 589 PRESENCE OF A SEXUAL PROBLEM MAY NOT AFFECT SEXUAL SATISFACTION: RESULTS FROM THE HOSPITALISED AND OUTPATIENTS’ PROFILE AND EXPECTATION STUDY (HOPES) Kirana P.S., Nakopoulou E., Papaharitou S., Moysidis K., Hatzimouratidis K., Salpigidis G., Hatzichristou D. Centre for Sexual and Reproductive Health, Aristotle University of Thessaloniki, Centre for Health Promotion, Thessaloniki, Greece Introduction & Objectives: Although epidemiological data have demonstrated a high prevalence of sexual problems, few men and women seek treatment. This phenomenon is not well understood and under explored. There is working hypothesis that not all people with sexual problems experience personal distress and therefore, despite the presence of and women reporting sexual problems. Material & Methods: HOPES is a hospital based survey investigating the relationship between psychosocial factors, patient-Centreedness, symptoms’ and health perception in a random sample of patients attending a general hospital. The design included a representative age (18-40, 41-60, 61-80 years) and gender. Subjective perception of sexual functioning was measured by the SCSF. Bother from sexual problems was measured by a single item: ‘how tests. Results: The sample (N=454) consisted of 51.1% women and 48.9% men (mean age function, the most frequently reported problems and also the most bothersome were reduced sexual desire and premature ejaculation, but among those reporting dissatisfaction from sexual function, erectile dysfunction was the most frequently reported and also most bothersome Conclusions: Approximately half of the hospitalized men and women reported a sexual data are important to understand the discrepancy between epidemiological studies on sexual function and number of men and women seeking treatment for sexual problems. Therefore, the presence of personal distress and not merely presence of sexual problem should be considered in epidemiological studies and prevention strategies. 590 FACTORS INFLUENCING PATIENT SATISFACTION AFTER 12 MONTHS TADALAFILTREATMENT: RESULTS FROM THE DETECT STUDY Perimenis P. 1 , Roumeguere T. 2 , Heidler H. , Roos E. 4 , Belger M. 5 , Schmitt H. 6 1 Patras Hospital, Dept. of Urology, Patras, Greece, 2 Erasmus Hospital, Dept. of Urology, Brussels, Belgium, Linz Hospital, Dept. of Urology, Linz, Austria, 4 Antonius Hospital, Dept. of Urology, Sneek, The Netherlands, 5 Eli Lilly, Dept. of Statistics, Erl wood, United Kingdom, 6 Eli Lilly, Dept. of Medicine, Brussels, Belgium Introduction & Objectives: To determine factors associated with patient satisfaction after 12 months Material & Methods: The DETECT study is an observational study in routine clinical practice in patients patients, data were available from 1567 patients after 12 months. Patients were assessed at baseline, 1, 6 and 12 months as part of their normal course of care. ED Inventory of Treatment Satisfaction (EDITS) scores were analysed at each time point. Mean EDITS scores (scale 0-4) were multiplied by 25 to normalize them to a 100 point scale. Results: total EDITS and individual questions scores. 1 month 6 months 12 months Total EDITS satisfaction score (mean, sd) 85.9(14.5) EDITS questions: Overall satisfaction with treatment Treatment met expectations Likelihood to continue treatment Easiness to use treatment Satisfaction how quickly treatment works Satisfaction how long treatment sexual activity Satisfaction of partner Preference of partner to continue treatment Naturalness of erection process Hardness of erections versus before ED 89.2(18.7) 91.0(16.7) 82.9(16.5) 80.6(20.1) 68.0(27.0) 86.5(18.4) 80.4(21.8) 86.7(18.5) 86.8(19.0) 75.1(22.4) 85.6(17.6) 87.9(18.5) 82.4(21.7) 86.6(17.7) 86.0(20.1) 77.2(22.9) 87.2(17.6) 75.0(25.5) at 12 months: 12 month non-severe IIEF EF ED categories, more sexual attempts, higher change in IIEF EF score from baseline, good tolerance to treatment, partner support, no relationship problems and higher observed in patient groups expressing higher satisfaction for each EDIT question. Conclusions: treatment tolerance at 12 months but also partner support and expectations at baseline. Patient satisfaction 591 TREATMENT WITH SILDENAFIL 50 MG OR 100 MG REDUCED ANXIETY LEVELS CONCERNING THE NEXT INTERCOURSE ATTEMPT IN MEN WITH ERECTILE DYSFUNCTION TREATED IN A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Stecher V.J. 1 , Stroberg P. 2 , Tseng L.J. 1 2 Urohalsan, Urology, Skovde, Sweden, Introduction & Objectives: The inability to have or successfully complete intercourse anxiety may always be present at some level in men with erectile dysfunction (ED), and can lead to escalating anxiety after a succession of intercourse failures. The impact of 50 mg or 100 mg. Material & Methods: The trial enrolled treatment-naive men with ED. After every occasion of sexual activity, the men completed an event log containing questions pertaining to several aspects of intercourse achievement (eg, erection hardness, maintenance of erections), including questions on the level of anxiety concerning the next attempt at sexual intercourse. Responses to the question, “Do you feel anxious about your next attempt at sexual intercourse?” included “no anxiety,” “slight anxiety,” “moderate anxiety,” and “highly anxious.” Event log data from baseline and the end of double-blind treatment phase were compared. Results: Most patients (mean age 51 years, range 20–65 years) had mild to moderate high anxiety about their next intercourse attempt. At the end of the double-blind phase, Conclusions: 592 VARENICLINE COMBINED WITH ON DEMAND SILDENAFIL 100 MG IN HEAVY SMOKERS COMPLAINING OF DIFFICULT-TO-TREAT ERECTILE DYSFUNCTION Salonia A.S., Pellucchi P.F., Matloob M.R., Gallina G.A., Dehò D.F., Briganti B.A., Barbieri B.L., Rocchini R.L., Abdollah A.F., Rigatti R.P., Montorsi M.F. Introduction & Objectives: Varenicline is a novel, selective nicotinic acethylcholine receptor partial agonist expressively developed for smoking cessation. The aim of this prospective study dysfunction (ED) non-responsive to phosphodiesterase type 5 inhibitors (PDE5-Is) alone by Material & Methods: From May to July 2007, 21 heavy smokers (namely, an average of 1 pack non-responsive to high dose PDE5-Is alone entered this study. Pre-treatment workup included a detailed medical and sexual history, including a semi-structured interview on recreational habits, and the self administration of the International Index of Erectile Function (IIEF). Patients were thus randomly segregated into Group 1 (n = 11), who were administered varenicline (e.g. visit was done at the 12-week of treatment, when pts completed both the IIEF and the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS). Results: complete data collection was available for 9 and 10 pts in Group 1 and 2, respectively. Two (18.2%) men in Group 1 discontinued varenicline because they did not quit smoking. In contrast, the 9 remaining pts in Group 1 ceased smoking at the 12-week assessment. Group 1 nausea, headache and insomnia were reported respectively by 2 (22.2%), 1 (11.1%) and 1 patients, respectively. Conclusions: The preliminary results of this , prospective, non placebo-controlled study seem to suggest that the combination of varenicline-induced acute smoke cessation and highest and a long-term follow-up study.